North America Metabolic Disorders Market Outlook to 2036 - Diabetes Assays and Cholesterol Tests

1.1 What Is This Report About?
1.2 Metabolic Disorders Market Segmentation
1.3 Definitions of Markets Covered in the Report

2.1 Metabolic Disorders Market, North America, Revenue ($m), 2024-2036
2.2 Metabolic Disorders Market, North America, Revenue ($m), 2024-2036
2.3 Metabolic Disorders Market, North America, Volume (Units), 2024-2036
2.4 Metabolic Disorders Market, North America, Volume (Units), 2024-2036
2.5 Metabolic Disorders Market, North America, Company Share by Revenue ($m), 2025

3.1 Metabolic Disorders Market, Canada, Revenue ($m), 2024-2036
3.1.1 Cholesterol Tests Market, Canada, Revenue ($m), by Segment, 2024-2036
3.1.2 Diabetes Assays Market, Canada, Revenue ($m), by Segment, 2024-2036
3.2 Metabolic Disorders Market, Canada, Volume (Units), 2024-2036
3.2.1 Cholesterol Tests Market, Canada, Volume (Units), by Segment, 2024-2036
3.2.2 Diabetes Assays Market, Canada, Volume (Units), by Segment, 2024-2036
3.3 Metabolic Disorders Market, Canada, Average Price ($), 2024-2036
3.4 Metabolic Disorders Market, Canada, Company Share by Revenue ($m), 2025

4.1 Metabolic Disorders Market, Mexico, Revenue ($m), 2024-2036
4.1.1 Cholesterol Tests Market, Mexico, Revenue ($m), by Segment, 2024-2036
4.1.2 Diabetes Assays Market, Mexico, Revenue ($m), by Segment, 2024-2036
4.2 Metabolic Disorders Market, Mexico, Volume (Units), 2024-2036
4.2.1 Cholesterol Tests Market, Mexico, Volume (Units), by Segment, 2024-2036
4.2.2 Diabetes Assays Market, Mexico, Volume (Units), by Segment, 2024-2036
4.3 Metabolic Disorders Market, Mexico, Average Price ($), 2024-2036
4.4 Metabolic Disorders Market, Mexico, Company Share by Revenue ($m), 2025

5.1 Metabolic Disorders Market, United States, Revenue ($m), 2024-2036
5.1.1 Cholesterol Tests Market, United States, Revenue ($m), by Segment, 2024-2036
5.1.2 Diabetes Assays Market, United States, Revenue ($m), by Segment, 2024-2036
5.2 Metabolic Disorders Market, United States, Volume (Units), 2024-2036
5.2.1 Cholesterol Tests Market, United States, Volume (Units), by Segment, 2024-2036
5.2.2 Diabetes Assays Market, United States, Volume (Units), by Segment, 2024-2036
5.3 Metabolic Disorders Market, United States, Average Price ($), 2024-2036
5.4 Metabolic Disorders Market, United States, Company Share by Revenue ($m), 2025

6.1 Metabolic Disorders Market Pipeline Products
6.2 Metabolic Disorders - Pipeline Products by Stage of Development
6.3 Metabolic Disorders - Pipeline Products by Segment
6.4 Metabolic Disorders - Pipeline Products by Territory
6.5 Metabolic Disorders - Pipeline Products by Regulatory Path
6.6 Metabolic Disorders - Pipeline Products by Estimated Approval Date

7.1 Abbott Laboratories
7.1.1 Company Overview
7.2 Siemens Healthineers AG
7.2.1 Company Overview
7.3 Roche Diagnostics International Ltd
7.3.1 Company Overview
7.4 Ortho Clinical Diagnostics Holdings Ltd (Inactive)
7.4.1 Company Overview
7.5 Beckman Coulter Inc
7.5.1 Company Overview

8.1 Corporate Communications
8.1.1 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors
8.1.2 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
8.1.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
8.1.4 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager
8.1.5 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
8.1.6 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research
8.1.7 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
8.2 Other Significant Developments
8.2.1 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
8.2.2 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors
8.2.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
8.2.4 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research
8.2.5 Oct 22, 2025: Visionary Holdings Launches Joint Venture in Toronto for Stem Cell Therapy Commercialization
8.2.6 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
8.2.7 Sep 23, 2025: Microbix Assisting EMQN With Second Genetic-Test EQA Program
8.2.8 Sep 22, 2025: Emergent BioSolutions Secures $29 Million in Product Orders from International Government Partner
8.3 Product News
8.3.1 Mar 11, 2026: PatentVest Announces Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics
8.3.2 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV
8.3.3 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
8.3.4 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
8.3.5 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
8.3.6 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies
8.3.7 Jun 23, 2025: New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease
8.4 Research And Development
8.4.1 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies
8.5 Strategy And Business Planning
8.5.1 Apr 14, 2026: Vida Health and OURA to Deliver Continuous, Personalized Metabolic Care
8.5.2 Mar 11, 2026: PatentVest Announces Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics
8.5.3 Nov 11, 2025: Expanse Medical Expands to Providence, Rhode Island
8.5.4 Nov 10, 2025: Synthego Introduces High-Performance Molecular Reagents for Diagnostics
8.5.5 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
8.5.6 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics
8.5.7 Oct 29, 2025: EazeBio And UC Santa Cruz Form Strategic Partnership For Instrument-Free Diagnostics
8.5.8 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research
8.5.9 Oct 22, 2025: Visionary Holdings Launches Joint Venture in Toronto for Stem Cell Therapy Commercialization
8.5.10 Sep 22, 2025: Emergent BioSolutions Secures $29 Million in Product Orders from International Government Partner

9.1 Research Methodology
9.1.1 Coverage
9.1.2 Secondary Research
9.1.3 Primary Research
9.1.4 Market Modeling and Forecasting
9.1.5 Company Share Analysis
9.1.6 Benchmarking
9.2 the Analyst Consulting
9.3 Contact Us
9.4 Disclaimer

Table 1: Metabolic Disorders Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2024-2036
Table 2: Metabolic Disorders Market, North America, Revenue ($m), USD Constant, 2024-2036
Table 3: Metabolic Disorders Market, North America, Volume (Units), 2024-2036
Table 4: Metabolic Disorders Market, North America, Volume (Units), 2024-2036
Table 5: Metabolic Disorders Market, North America, Company Share by Revenue ($m), 2025
Table 6: Metabolic Disorders Market, Canada, Revenue ($m), USD Constant, 2024-2036
Table 7: Cholesterol Tests Market, Canada, Revenue ($m), USD Constant, 2024-2036
Table 8: Diabetes Assays Market, Canada, Revenue ($m), USD Constant, 2024-2036
Table 9: Metabolic Disorders Market, Canada, Volume (Units), 2024-2036
Table 10: Cholesterol Tests Market, Canada, Volume (Units), 2024-2036
Table 11: Diabetes Assays Market, Canada, Volume (Units), 2024-2036
Table 12: Metabolic Disorders Market, Canada, Average Price ($), 2024-2036
Table 13: Metabolic Disorders Market, Canada, Company Share by Revenue ($m), USD Constant, 2025
Table 14: Metabolic Disorders Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Table 15: Cholesterol Tests Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Table 16: Diabetes Assays Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Table 17: Metabolic Disorders Market, Mexico, Volume (Units), 2024-2036
Table 18: Cholesterol Tests Market, Mexico, Volume (Units), 2024-2036
Table 19: Diabetes Assays Market, Mexico, Volume (Units), 2024-2036
Table 20: Metabolic Disorders Market, Mexico, Average Price ($), 2024-2036
Table 21: Metabolic Disorders Market, Mexico, Company Share by Revenue ($m), USD Constant, 2025
Table 22: Metabolic Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 23: Cholesterol Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 24: Diabetes Assays Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 25: Metabolic Disorders Market, United States, Volume (Units), 2024-2036
Table 26: Cholesterol Tests Market, United States, Volume (Units), 2024-2036
Table 27: Diabetes Assays Market, United States, Volume (Units), 2024-2036
Table 28: Metabolic Disorders Market, United States, Average Price ($), 2024-2036
Table 29: Metabolic Disorders Market, United States, Company Share by Revenue ($m), USD Constant, 2025
Table 30: Metabolic Disorders Market Pipeline Products
Table 31: Metabolic Disorders - Pipeline Products by Stage of Development
Table 32: Metabolic Disorders Companies - Pipeline Products by Stage of Development
Table 33: Metabolic Disorders - Pipeline Products by Segment
Table 34: Metabolic Disorders - Pipeline Products by Territory
Table 35: Metabolic Disorders - Pipeline Products by Regulatory Path
Table 36: Metabolic Disorders - Pipeline Products by Estimated Approval Date
Table 37: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

Figure 1: Metabolic Disorders Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2024-2036
Figure 2: Metabolic Disorders Market, North America, Revenue ($m), USD Constant, 2024-2036
Figure 3: Metabolic Disorders Market, North America, Volume (Units), 2024-2036
Figure 4: Metabolic Disorders Market, North America, Volume (Units), 2024-2036
Figure 5: Metabolic Disorders Market, North America, Company Share (%), 2025
Figure 6: Metabolic Disorders Market, Canada, Revenue ($m), USD Constant, 2024-2036
Figure 7: Cholesterol Tests Market, Canada, Revenue ($m), USD Constant, 2024-2036
Figure 8: Diabetes Assays Market, Canada, Revenue ($m), USD Constant, 2024-2036
Figure 9: Metabolic Disorders Market, Canada, Volume (Units), 2024-2036
Figure 10: Cholesterol Tests Market, Canada, Volume (Units), 2024-2036
Figure 11: Diabetes Assays Market, Canada, Volume (Units), 2024-2036
Figure 12: Metabolic Disorders Market, Canada, Company Share (%), 2025
Figure 13: Metabolic Disorders Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Figure 14: Cholesterol Tests Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Figure 15: Diabetes Assays Market, Mexico, Revenue ($m), USD Constant, 2024-2036
Figure 16: Metabolic Disorders Market, Mexico, Volume (Units), 2024-2036
Figure 17: Cholesterol Tests Market, Mexico, Volume (Units), 2024-2036
Figure 18: Diabetes Assays Market, Mexico, Volume (Units), 2024-2036
Figure 19: Metabolic Disorders Market, Mexico, Company Share (%), 2025
Figure 20: Metabolic Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 21: Cholesterol Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 22: Diabetes Assays Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 23: Metabolic Disorders Market, United States, Volume (Units), 2024-2036
Figure 24: Cholesterol Tests Market, United States, Volume (Units), 2024-2036
Figure 25: Diabetes Assays Market, United States, Volume (Units), 2024-2036
Figure 26: Metabolic Disorders Market, United States, Company Share (%), 2025
Figure 27: Metabolic Disorders - Pipeline Products by Stage of Development
Figure 28: Metabolic Disorders - Pipeline Products by Segment
Figure 29: Metabolic Disorders - Pipeline Products by Territory
Figure 30: Metabolic Disorders - Pipeline Products by Regulatory Path
Figure 31: Metabolic Disorders - Pipeline Products by Estimated Approval Date